Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=3&sort=-program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1392&sort=-program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=4&sort=-program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-program_officials" }, "data": [ { "type": "Grant", "id": "15414", "attributes": { "award_id": "1U24AI183849-01", "title": "The Bacterial and Viral Bioinformatics Resource Center (BV-BRC)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32022, "first_name": "WIRIYA", "last_name": "Rutvisuttinunt", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-18", "end_date": "2029-06-30", "award_amount": 3600000, "principal_investigator": { "id": 32023, "first_name": "RICK L.", "last_name": "STEVENS", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "The mission of the NIH/NIAID Bioinformatics Resource Center (BRC) program is to accelerate basic and applied infectious disease research by providing access to cutting edge bioinformatic tools, knowledgebases, and expertise, ensuring that our knowledge of pathogenesis can be translated into diagnostics, therapeutics and a public health response that mitigates the morbidity and mortality resulting from infectious diseases. The current NIH/NIAID-funded Bacterial and Viral Bioinformatics Resource Center (BV-BRC; Contract No. 75N93019C00076) supported this mission by providing a bioinformatics knowledgebase and analysis platform covering all bacterial and viral pathogens. In response to the NIAID notice of funding opportunity, RFA-AI-23- 032, our proposal intends to maintain, improve, and expand the BV-BRC to combat future infectious disease threats, while maintaining our commitment to enhance diversity, equity, inclusion, and accessibility, fostering a more inclusive scientific community, and ensuring equitable access to bioinformatics resources. BV-BRC will support bacteria, archaea, viruses, bacteriophages, as well as metagenomic analyses, with particular emphasis on the microbiomes and viromes related to infectious disease and public health. BV-BRC will continue to support the basic scientific research necessary to understand the biology of these organisms, their pathogenesis, and disease processes; support development of diagnostics and therapeutics to combat pathogenic organisms; and provide a rapid response framework to effectively deal with the inevitable and unpredictable outbreaks and pandemics. To support these overarching goals, we propose to extend and enhance BV-BRC through the following four key elements: 1) Maintain and enhance the BV-BRC knowledgebase to support exponential growth of data and usage and provide integrated access to omics data, metadata, analysis services and visualization tools, private user workspace, and user documentation to allow users to analyze public and private data and share or publish results; 2) Develop innovative tools and technologies to provide comprehensive services for viral and bacterial bioinformatics, metagenomics, drug development, and developing AI-driven natural language-based user interface for interacting with data and tools, with emphasis on improving user experience; 3) Offer critical bioinformatics expertise, outreach, and training to the community, with emphasis on fostering opportunities for students and researchers from minority and underserved communities by providing freely accessible training material and conducting training for instructors from underrepresented institutions, with particular focus on Minority Serving Institutions (MSIs); and 4) Provide cutting-edge support to rapidly respond to emerging needs, outbreaks, and pandemic preparedness by building on the tools and procedures developed during COVID-19 and Mpox pandemics and enhancing them to improve readiness and response to future outbreaks and pandemics.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15413", "attributes": { "award_id": "1UG3AI181797-01", "title": "Coordinating and Data Sharing Center - R&D of Vaccines and Antibodies for Pandemic Preparedness (ReVAMPP)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32019, "first_name": "ANNE ELIZABETH MAYER", "last_name": "Bridwell", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-16", "end_date": "2027-06-30", "award_amount": 7994888, "principal_investigator": { "id": 32020, "first_name": "Sean Thomas", "last_name": "Hanlon", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32021, "first_name": "Gregory D", "last_name": "Sempowski", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 809, "ror": "", "name": "RESEARCH TRIANGLE INSTITUTE", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "0BPROJECT SUMMARY/ABSTRACT The global pandemic caused by SARS-CoV-2 highlighted the continual threat of emerging and re-emerging pandemic-potential pathogens and the critical value of coordinated multidisciplinary basic and translational research for pandemic preparedness. There is an urgent need for an integrated collaborative effort to build a robust basic research and translational science portfolio for preparedness against high-risk viral families including Paramyxoviridae, Picornaviridae, and Bunyavirales. The National Institute of Allergy and Infectious Diseases (NIAID) is supporting the development of the Research and Development of Vaccines and Monoclonal Antibodies for Pandemic Preparedness (ReVAMPP) Network to fill this critical gap. The overall goal of this new collaborative Network, consisting of a Coordinating and Data Sharing Center (CDSC) and six to eight Research Centers, is to collaboratively produce generalizable knowledge that enables a rapid response when previously understudied or unknown pathogens emerge. RTI International’s well-established track record implementing large-scale domestic and international coordinating and data management centers, including in the emerging infectious disease ecosystem, makes us well qualified to develop and provide Network governance, communications, and data sharing and analysis as the ReVAMPP CDSC. The overall goal of the RTI-based CDSC is to establish and maintain an integrated Network to accelerate discovery and dissemination of novel vaccine and monoclonal antibody strategies to prepare for the next pandemic outbreak. To accomplish this goal, RTI proposes a CDSC organizational structure, consisting of two interconnected teams under mPIs and a Project Director—an Administration and Leadership Team, and a Data Management and Analysis Team. This structure leverages RTI multidisciplinary experts and will provide ReVAMPP Centers, NIAID, and stakeholders centralized administrative, communication, and operational support for Network-wide activities, while also establishing data sharing and analysis standards and platforms. The Specific Aims of the RTI-based CDSC align with these two teams and will use both established and novel innovative approaches and technologies to (Aim 1) coordinate preparatory vaccine and antibody strategy research by establishing and maintaining ReVAMPP Network governance, administration, and communication; and (Aim 2) accelerate transparent collaborative vaccine and antibody strategy research by developing and maintaining a secure ReVAMPP Network Private Portal that includes centralized resource, data sharing, and reporting systems. This independent, but integrated team of administrators, communicators, and data science experts embedded within the ReVAMPP Network as the CDSC, will coordinate, facilitate, and empower Network investigators and NIAID to proactively prepare to rapidly share information with key stakeholders across the globe when new viral pandemic/outbreaks occur.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15412", "attributes": { "award_id": "1R21AI185841-01", "title": "Optimization of novel inhibitors of mycolic acid synthesis as TB drug candidates.", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32016, "first_name": "Jim P.", "last_name": "Boyce", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-17", "end_date": "2026-06-30", "award_amount": 237288, "principal_investigator": { "id": 32017, "first_name": "Kyle H", "last_name": "Rohde", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 32018, "first_name": "Jennifer Marie", "last_name": "Schomaker", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 1475, "ror": "https://ror.org/036nfer12", "name": "University of Central Florida", "address": "", "city": "", "state": "FL", "zip": "", "country": "United States", "approved": true }, "abstract": "Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is responsible for staggering levels of morbidity and mortality, with ~1.7 million deaths and ~10 million new cases each year. The current TB regimens for drug susceptible strains, entailing multidrug cocktails for ≥4 months, leave much to be desired. The cost and logistics of administering standard of care regimens over many months and the inability of many patients to tolerate the debilitating side effects further complicate the clinical control of TB. The lingering negative impacts of the COVID pandemic on TB control efforts and increasing challenge of multidrug-resistant Mtb strains, which have only a ~50% treatment success rate, further highlight the urgent need for better antibiotics to tackle this problem. Even our definition of what “better” means has shifted based on recent appreciation of the heterogeneity of mycobacteria subpopulations that must be eradicated, including replicating and non-replicating bacilli residing both extracellularly and within host cells in diverse microenvironments. Thus, effective drug combinations must not only access mycobacteria within different niches and layers of granulomas but also be able to kill Mtb in many distinct metabolic states while minimizing the emergence of resistance. In order to meet this urgent need for game-changing new treatment options for TB, it is imperative to maintain a robust pipeline of new anti-TB drug candidates with the potential to meet these demanding performance criteria. This project seeks to address this need by building on our recent discovery of a first-in-class series of compounds that kill Mtb via inhibition of a well- validated but underexploited target enzyme essential for cell wall synthesis. Thus far, we have demonstrated sub-micromolar potency, enhanced potency against Mtb within macrophages, high specificity for Mtb, and high selectivity over mammalian cells. We have strong evidence that these compounds act via inhibition of an essential enzyme involved in mycolic acid biosynthesis for which there are currently no viable preclinical candidates. The first major goal of this project is hit-to-lead optimization and elucidation of structure-activity relationships, using whole cell potency and ADME/PK properties as key drivers of compound prioritization. Secondly, we will employ orthogonal approaches to further validate the target and ensure that optimized lead compounds remain on-target. Successful completion of this project will set the stage for subsequent lead optimization and in vivo efficacy studies of a promising new class of cell-wall targeting TB antibiotics.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15415", "attributes": { "award_id": "1R13AI186427-01", "title": "CSHL 2024 Microbiome Conference", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32014, "first_name": "Patricia M.", "last_name": "Strickler-Dinglasan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-17", "end_date": "2025-06-30", "award_amount": 6500, "principal_investigator": { "id": 23978, "first_name": "DAVID J.", "last_name": "STEWART", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 992, "ror": "https://ror.org/02qz8b764", "name": "Cold Spring Harbor Laboratory", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 992, "ror": "https://ror.org/02qz8b764", "name": "Cold Spring Harbor Laboratory", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "MICROBIOME Conference October 29 – November 2, 2024 The fourth installment of the international Microbiome conference at Cold Spring Harbor Laboratory will include the latest research exploring the etiology and treatment of a wide-range of microbe-associated diseases, integrating the disciplines of clinical research, microbiology, immunology, ecology, bioinformatics and genomics. From the prior meetings in 2019 (inaugural, in-person), 2020 (virtual due to COVID), 2022 (hybrid), it was clear that the CSHL Microbiome meeting offers a unique forum where a wide variety of disciplines come together to catalyze new ideas and integrate approaches focused on the myriad roles microbiomes play in human health. The explicitly broad definition of microbiomes discussed at this conference will allow for continued mutual fertilization of ideas, techniques and theories developed by researchers active in clinical, ecological and evolutionary lines of research. As well as bringing established leaders as speakers, this meeting will focus on young investigators and trainees to facilitate the scientific interactions necessary to grow this field and develop novel clinical and experimental approaches, diagnostics and therapies. The meeting will provide an in-depth focus on both experimental and computational approaches that are being used to elucidate the mechanisms of microbial community assembly, inflammatory, immunologic and infectious diseases. We will also explore novel roles for the microbiome in drug metabolism and response. Microbiome studies that are featured in the oral presentations will include bacterial, fungal and viral associated disease, and include microbe- microbe interactions. Oral and poster sessions will focus on major themes of microbiome and the host response, including Pathogens and Microbial Communities; Using all the Data: Bioinformatic Analyses; Microbial Molecules and Interactions; Microbes as Machines; Environment and The Microbiome; Microbial Function, Host Response; Human and Animal Model Studies; Microbial Ecology and Evolution. The meeting will include two plenary keynote speakers invited to give longer talks. The oral sessions will begin with two invited talks from established leaders in the field, followed by 6 shorter talks chosen from submitted abstracts. The inclusion of poster sessions as well as the allotment of ample time for questions following each talk will encourage extensive discussion between the participants. The meeting will be small enough (250 - 350 scientists attending in-person, with an additional virtual audience to broaden access) to facilitate these interactions, yet large enough to allow for oral presentations from younger investigators and those with novel perspectives. The integration of a wide variety of aspects of microbiome research will nucleate new interdisciplinary interactions that will drive this innovative translational field. This meeting will be distinct in the opportunities for young investigators to present their work and the coalescence of computational, experimental and clinical disciplines.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15411", "attributes": { "award_id": "1R13AI186420-01", "title": "Mechanisms of RNA Decay", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32014, "first_name": "Patricia M.", "last_name": "Strickler-Dinglasan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-16", "end_date": "2024-11-30", "award_amount": 5000, "principal_investigator": { "id": 32015, "first_name": "Olivia Selfridge", "last_name": "Rissland", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1511, "ror": "", "name": "FEDERATION OF AMER SOC FOR EXPER BIOLOGY", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "A counterbalance to RNA synthesis, RNA degradation is critical for regulating gene expression. The understanding that RNA degradation is critical for gene expression traces back to 1959 when Pardee, Jacob and Monod demonstrated in a historical paper that there had to be an unstable intermediate directing protein synthesis. Groundbreaking research over the past decades led to the identification of a variety of specific and tightly regulated RNA decay pathways and biochemical characterization of the enzymes involved in them, both in eukaryotic and prokaryotic organisms. The clinical applications in the post-transcriptional regulation/RNA field are now being realized with the initial development of Nusinersen/Spinraza® to successfully treat Spinal Muscular Atrophy and the more recent description of Milasin® to treat a single patient through a personalized RNA therapy. Of course, in 2020, RNA burst onto the global stage in a way we could not have predicted with the COVID-19 RNA virus impacting life as we know it across the globe. Who would or could have guessed that RNA could also represent a potential path back to a new normal via the rapid development and deployment of the first mRNA vaccines. All these examples highlight why the FASEB meeting on ‘Mechanisms of RNA Decay’ is timely. This meeting has developed into a unique conference that brings together the leading experts in RNA decay in humans and other metazoan animals, plants, fungi, viruses, and bacteria. This meeting is the 13th is a series of FASEB meetings on this topic where there is a long tradition of sharing key discoveries, building collaborations, and contributing to career development for junior scientists in the field. This meeting, held August 18–22, 2024 in Lisbon, Portugal, is co-organized by three leaders in the RNA decay field, Dr. Olivia Rissland from University of Colorado School of Medicine, USA, Dr. Alicia Bicknell from Moderna Therapeutics, and Dr. Oliver Muhlemann from University of Bern, Switzerland. We propose three specific aims for this meeting: 1) Bringing together the international community working on RNA degradation and providing an intellectually stimulating and mutually supportive forum for the presentation and discussion of the latest advances in the field; 2) Providing an inclusive and friendly environment for establishing collaborations between researchers studying RNA degradation with different approaches and in different organisms; and 3) Encouraging productive interactions between a diverse group of both junior scientists and world leaders in the RNA degradation field. In keeping with the meeting goals, the organizers are committed to inclusive excellence: Among the 28 invited speakers, there are 13 women (46%) and a well-balanced gender ratio will be ensured among the 25 additional oral presentations that will be selected from the submitted abstracts. Also, among the 10 session chairs, six are women. We are excited to include trainee co-chairs, who will be selected from the short-talk presenters. The long-term goal is to continue a successful meeting series that addresses modern and timely topics in RNA decay and strengthens the interactions within a diverse and inclusive community of collaborative scientists and colleagues.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15408", "attributes": { "award_id": "4R00GM141482-03", "title": "Role of mitochondrial/ER contacts in the regulation of mtDNA release from mitochondria, innate immune signaling, and responses to viral infection", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 32011, "first_name": "Kalynda K", "last_name": "Stokes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-15", "end_date": "2027-05-31", "award_amount": 248999, "principal_investigator": { "id": 24043, "first_name": "Laura Elizabeth", "last_name": "Newman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1688, "ror": "https://ror.org/03xez1567", "name": "Salk Institute for Biological Studies", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 908, "ror": "https://ror.org/0153tk833", "name": "University of Virginia", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "Innate immunity is critical for human health, allowing cells to detect and combat invasion by pathogens. Mitochondria are essential organelles that play important roles within the regulation of innate immune pathways. Contact sites between mitochondria and the endoplasmic reticulum (mitochondria/ER contacts, or MERCs) are important for mitochondrial homeostasis (such as replication of mitochondrial DNA, or mtDNA), but also act as signaling platforms for antiviral responses to viral dsRNA. However, the role of MERCs in the regulation of innate immune responses to cytoplasmic DNA is not well understood. In addition, mtDNA activates innate immune pathways when released from mitochondria into the cytoplasm. Dr. Laura Newman has found that MERCs stimulate the release of mtDNA in response to stalled mtDNA replication caused by mtDNA damage. Though it is well-established that cytoplasmic mtDNA enhances antiviral defenses, whether MERCs regulate mtDNA release during viral infection is unknown. Certain DNA viruses (HSV-1 and EBV) damage mtDNA directly or inhibit its replication, suggesting that removal of mtDNA (and its antiviral properties) may aid viral replication. This provides an ideal model system to test whether MERCs mediate release of damaged mtDNA during infection. In addition, RNA viruses disrupt the ER and MERCs to replicate. Release of mtDNA from mitochondria occurs during infection by several RNA viruses (such as influenza); therefore, MERCs may also mediate mtDNA release in response to RNA viral infection. The central hypothesis is that MERCs regulate mtDNA release and coordinate dsRNA and DNA innate immune responses to amplify cellular antiviral defenses. Aim #1 examines whether MERCs stimulate mtDNA release during HSV-1 or EBV infection, and whether mtDNA release into the cytosol benefits the host cell or virus. Aim #2 builds upon Dr. Newman’s preliminary data that the mitochondrial protein MFN1 enhances innate immune responses to cytoplasmic DNA, and tests whether MFN1 complexes with two innate immune adaptors that sense DNA (STING) and dsRNA (MAVS) at MERCs to regulate antiviral defenses. Lastly, Aim #3 examines whether RNA viruses (Influenza A and SARS-CoV-2) disrupt MERCs, causing stalled mtDNA replication and release, and whether this enhances antiviral defenses. Successful completion of any aim will provide important insights into the regulation of antiviral defenses, possibly informing new therapeutic targets to limit viral infection. This research will also provide virology training to the candidate, and research on viral-mitochondrial interactions will be carried over to her own lab. This award will enable Dr. Newman to take advantage of virology and immunology expertise via her advisory committee (Drs. O’Shea and Kaech), as well as additional career development opportunities at the Salk Institute. This will aid her transition to an independent scientist specializing in the role of mitochondria within innate immune pathways, which is a rapidly expanding and important area of scientific research.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15406", "attributes": { "award_id": "1F32MD019534-01", "title": "Examining Racial Disparities in Predictive Modeling Among Survivors of Critical Illness", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 32008, "first_name": "ARUNDHATI", "last_name": "Gogineni", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-01", "end_date": "2026-06-30", "award_amount": 90932, "principal_investigator": { "id": 32009, "first_name": "Hiam", "last_name": "Naiditch", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 848, "ror": "", "name": "UNIVERSITY OF PITTSBURGH AT PITTSBURGH", "address": "", "city": "", "state": "PA", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY/ABSTRACT: Survivors of critical illness often face significant challenges, such as neurocognitive disorders, physical disabilities, and respiratory limitations. Healthcare disparities by race heighten such challenges. Risk prediction tools designed to identify high-risk patients for interventions such as post-acute care clinics may exacerbate existing bias among racial and ethnic groups. Intending to address bias in prediction tools for survivors of critical illness, our team brings expertise in health services research focusing on healthcare disparities, statistical modeling, and causal inference. In previous work, we have highlighted racial differences in patients with cardiovascular disease and COVID-19 across different healthcare systems, including the Veterans Health Administration (VHA). Furthermore, we have begun exploring outcomes among survivors of critical illness including mortality and re-admission rates and developed an innovative post-ICU care model showing early indications of reducing hospital readmissions, increasing hospital-free days, and reducing mortality across diverse patient populations. As an F32 grant recipient, I will integrate and build on the expertise of my mentorship to identify and characterize racial disparities within three datasets of critical care illness survivors as defined by mortality, 90-day re-admissions, and hospital-free days (HFDs) at 90 days. In parallel, I will compare bias within two statistical models used to stratify patients by one-year mortality: (1) the Care Assessment Needs (CAN) score, a mortality risk model widely used to guide interventions among Veterans, and (2) the PREDICT score, a simplified one-year mortality risk model used at first patient contact to guide interventions such as palliative care consultation. Statistical fairness is an emerging concept geared toward reducing bias within statistical models and algorithms. To address any identified bias within our models, our team will employ novel approaches to achieve statistical fairness, including double prioritization. In addition to identifying healthcare disparities within a population of increasing care complexity, my proposal investigates statistical models as underlying contributors to healthcare disparities, aiming to rectify such inequalities through refined and equitable modeling approaches. In doing so, we propose establishing a fair care delivery framework for critical illness survivors. With close mentorship from an experienced team in healthcare disparities research, healthcare delivery, and innovative research methodologies at the University of Pittsburgh, this training plan forms a foundation for a Career Development Award and a future career as a physician-scientist.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15394", "attributes": { "award_id": "1P30GM154632-01", "title": "Center for Targeted Therapeutics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of General Medical Sciences (NIGMS)" ], "program_reference_codes": [], "program_officials": [ { "id": 31995, "first_name": "WUHONG", "last_name": "Pei", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-07-15", "end_date": "2029-05-31", "award_amount": 1117500, "principal_investigator": { "id": 31996, "first_name": "Hippokratis", "last_name": "Kiaris", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 930, "ror": "", "name": "UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA", "address": "", "city": "", "state": "SC", "zip": "", "country": "United States", "approved": true }, "abstract": "The Center for Targeted Therapeutics (CTT) was established in 2014 at the University of South Carolina (USC), with the mission to develop the institutional research in the area of experimental therapeutics aimed at molecular targets implicated in different pathologies. The Center has been transformative for translational biomedical research at USC. In phases 1 and 2, CTT has supported the research and mentoring of 15 junior faculty from several different Colleges who served as Research Project Leaders (RPL). Subsequently the RPLs have won 13 R01s and several smaller grants; 11 of them have been promoted to Associate or full Professor. In addition, 23 pilot projects were funded, with the pilot project leaders (PPL) subsequently winning 4 R01s and several smaller grants. Subsequent to CTT funding, the RPLs and PPLs published more than 300 articles and won over $50M in external funding, filed multiple patents and brought their drug candidates into the clinical trial pipeline. The CTT supported the recruitment of 9 junior faculty members and engaged at least three SmartState Endowed Chairs related to Targeted Therapeutics. CTT supports the operation of three resource cores: Functional Genomics, Microscopy and Flow Cytometry, and Drug Discovery Synthesis, that provide state-of-the-art services to investigators at USC and the State of SC. At the onset of COVID19 pandemic, the Functional Genomics core rapidly developed the SARS-Cov2 testing pipeline that, in the form of a CLIA lab, served the USC community throughout the pandemic. CTT also sponsored a special Pilot Project program in COVID19 therapeutics. During Phase 3, CTT will transition to self-sufficiency and sustainability, leveraging the progress attained so far by pursuing the following activities: 1). Support high-impact research projects in Targeted Therapeutics, by funding pilot projects, identifying scientific priority areas, and promoting collaborations in the area of Targeted Therapeutics. The pilot project awards will prioritize junior faculty, collaborative studies and the workforce diversification by engaging investigators that belong to or serve underserved groups. 2). Maintain and grow sustainable research infrastructure by supporting three strategic resource Cores: the Functional Genomics Core, the Drug Design and Synthesis Core, and the Microscopy and Flow Cytometry Core. 3). Assure long-term development of the CTT by broadening collaborative networking in Targeted Therapeutics. For this purpose, CTT will conduct Center meetings, arrange scientific seminars and promote external collaborations. CTT will also organize individual training and workshops aimed at developing multi-investigator and SBIR/STTR grant applications. CTT will work in alignment with Institutional priorities at USC to assure the sustainability of CTT research cores’ operation and continuous engagement and expansion of the critical mass of Targeted Therapeutics investigators that has been established during Phases 1 and 2. The CTT will promote the mission of the NIH IDeA program and will enhance the State's stature in Targeted Therapeutics research, continuing to make an impact on the public health, scientific education and economic development of the State.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15379", "attributes": { "award_id": "1R13FD008331-01", "title": "2024 FDA Retail Food Protection Seminar and Illinois Environmental Health Association’s Annual Education Conference", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 31980, "first_name": "Danielle", "last_name": "Head", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-30", "end_date": "2025-08-31", "award_amount": 50000, "principal_investigator": { "id": 31981, "first_name": "Anna Marie", "last_name": "Yates", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 2538, "ror": "", "name": "ILLINOIS ENVIRONMENTAL HEALTH ASSOCIATION", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "FDA Support for Conferences and Scientific Meetings Funding Opportunity Announcement (FOA) Number: PAR-23-072 Participant: Illinois Environmental Health Association Program Dates: July 2024- December 2024 Project Summary Illinois Environmental Health Association is seeking funding from the FDA for the FDA Support for Conferences and Scientific Meetings Funding Opportnity. The funding will be used for the FDA/ IEHA Retail Food Seminar and Annual Education Conference in Chicago, Illinois. The Conference will be September 11-13, 2024 focusing on Food Safety. Our goal is to provide an opportunity for surrounding states to send their food program staff to a two and half day seminar where they will gain knowledge of food safety topics. Since the covid pandemic, it is pertinent that we continue providing opportunities for states to network and collaborate to keep up with the growing food integration. Our goal is to showcase the past, present, and future of public health through speakers and topics.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15372", "attributes": { "award_id": "1R21NR021040-01A1", "title": "Barriers to Screen for Domestic Violence among Women in Emergency Department", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Nursing Research (NINR)" ], "program_reference_codes": [], "program_officials": [ { "id": 31971, "first_name": "Dara", "last_name": "Blachman", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-09-25", "end_date": "2026-08-31", "award_amount": 432542, "principal_investigator": { "id": 31972, "first_name": "Azade", "last_name": "Tabaie", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1515, "ror": "", "name": "MEDSTAR HEALTH RESEARCH INSTITUTE", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Domestic violence (DV) includes physical and sexual violence, threats, economic, and emotional/psychological abuse, or other abusive behavior as part of a systematic pattern of control and power perpetrated by one intimate partner against another. It causes a significant burden for the healthcare systems by increasing morbidity and mortality among victims. Women are disproportionately affected, although men may experience DV as well. The recent COVID-19 pandemic led to movement restrictions and stay at home orders. While these decisions were essential to prevent spread of the virus, such extended domestic stays may exacerbate the number the total as well as reported incidents of DV. As a result, in recent years, DV has transformed into a shadow pandemic, which further complicated this public health issue and increased the need to perform accurate and timely interventions. DV often forms a pattern, and many of the victims experience repeated acts of physical or mental abuse. Victims of DV may seek care in hospital settings which makes timely interventions critical and even lifesaving. While there is a serious need for government to reinforce commitments made to eliminate all forms of DV against women, the health sector plays an essential role in breaking the cycle of abuse. Health providers can prevent reoccurrence of such violent incidents by identifying women who are experiencing DV, and then provide comprehensive services and train health providers in responding to the needs of survivors in addition to caring for physical injuries. Abused women rarely disclose the reason for emergency department (ED) visit due to various reasons including shame, fear of the perpetrator or financial dependencies. While these factors form patient-specific barriers to screen for DV, the barriers to screening, detecting and helping DV victims can be recognized at different levels during an ED visit. Since these barriers are not clear, more exploration is needed to understand important features by analyzing EHR data to gain further understanding of the clinical experience and environment. In Aim 1 of this proposal, we will use the DV-related ICD-9/ICD-10 diagnosis codes to find positive cases of DV among the visits to ED. Then adapt market-basket analysis, which is a data mining method originated in the field of marketing, to our objective and identify patterns of injury and health problems which are observed together frequently. Then, we will utilize state-of-the-art deep learning-based natural language processing (NLP) models to learn the patterns in electronic health records clinical notes related to DV. In Aim 2, we will conduct semi- structured interviews with ED health providers to investigate the barriers to screening for DV during patient- provider encounter. The outcomes of this study have the potential to add significant insights to improve the screening process and the care we provide our patients in the ED. 1", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 3, "pages": 1392, "count": 13920 } } }